Proteomics International (ASX:PIQ) - Managing Director, Dr Richard Lipscombe
Managing Director, Dr Richard Lipscombe
Source: Proteomics International
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Proteomics International Laboratories (PIQ) engages Biotem to manufacture its test kits
  • The test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease using a simple blood test
  • The agreement spans over three years, with the option to extend for additional periods of one year
  • Proteomics shares were up 8.61 per cent, trading at $1.14 at 3:50 pm AEST

Proteomics International Laboratories (PIQ) has contracted a French immunoassay specialist to manufacture its test kits.

The company, Biotem, has been contracted to manufacture test kits for the PromarkerD predictive test for diabetic kidney disease, using a ‘fingerprint’ of protein biomarkers in the blood.

The test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease using a simple blood test.

“Now, by contracting these specialist manufacturers we are building our production capacity to meet our anticipated demand for the test in the Northern Hemisphere and worldwide,” said Proteomics’ managing director, Dr Richard Lipscombe.

The agreement spans over three years, with the option to extend for additional periods of one year. During this time, Biotem will manufacture PromarkerD test kits on a fee-for-service basis.

The announcement follows reagent producer, Abcam being contracted for a world first predictive test for diabetic kidney disease.

“The engagement of global manufacturing partners will help accelerate the worldwide roll-out of PromarkerD, as well as the commercialisation of our pipeline of other diagnostics under development,” said Dr Lipscombe.

Proteomics shares were up 8.61 per cent, trading at $1.14 at 3:50 pm AEST.

PIQ by the numbers
More From The Market Herald
The Market Herald Video

" PharmAust (ASX:PAA) faces delays for COVID-19 trial

PharmAust (ASX:PAA) is facing delays for its phase one COVID-19 trial as it works to find…
The Market Herald Video

" Creso Pharma (ASX:CPH) eyes Australian body care market with Dr Pickles deal

Creso Pharma (ASX:CPH) has signed a heads of agreement with tattoo aftercare specialist Dr Pickles.
The Market Herald Video

" Knosys (ASX:KNO) wins contract with Healthdirect Australia

Knosys (ASX:KNO) has won a contract with Healthdirect Australia for its Knowledge Management platform, KnowledgeIQ.
The Market Herald Video

" Oneview Healthcare (ASX:ONE) expands partnership with BJC Health System

Oneview Healthcare (ASX:ONE) has signed deal with BJC Health System to deploy the Oneview platform group-wide,…